The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...
For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) ...
Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid ...
For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement ...
The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.
New analyses bolster the case for tricuspid TEER and reassure on outcomes in patients with implanted electronic devices.
Amir Danino, CEO of Innoventric, stated: “Our mission is to revolutionize tricuspid regurgitation care with minimally invasive therapies that significantly improve patient outcomes. The strong backing ...
Edwards Lifesciences (NYSE:EW) today announced data highlighting the superiority of its Evoque system compared to medical ...
The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...
In this cohort study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) had strong psychometric properties in patients with ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...
Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.